1RKLB Fundamental Analysis - ROCKET LAB CORP

Name: ROCKET LAB CORP (1RKLB) Stock
Brand: ROCKET LAB CORP
Rating: 4.5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to 1RKLB. 1RKLB was compared to 45 industry peers in the Aerospace & Defense industry. The financial health of 1RKLB is average, but there are quite some concerns on its profitability. 1RKLB is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year 1RKLB has reported negative net income.

1RKLB had a negative operating cash flow in the past year.

1RKLB had negative earnings in each of the past 5 years.

1RKLB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of 1RKLB (-8.90%) is worse than 91.11% of its industry peers.

The Return On Equity of 1RKLB (-15.43%) is worse than 84.44% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.9%
ROE	-15.43%
ROIC	N/A

ROA(3y)-16.4%

ROA(5y)-18.08%

ROE(3y)-34.28%

ROE(5y)-34.08%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 31.70%, 1RKLB perfoms like the industry average, outperforming 53.33% of the companies in the same industry.

The Profit Margin and Operating Margin are not available for 1RKLB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	31.7%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

1RKLB does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for 1RKLB has been increased compared to 1 year ago.

The number of shares outstanding for 1RKLB has been increased compared to 5 years ago.

1RKLB has a worse debt/assets ratio than last year.

2.2 Solvency

1RKLB has an Altman-Z score of 11.81. This indicates that 1RKLB is financially healthy and has little risk of bankruptcy at the moment.

With an excellent Altman-Z score value of 11.81, 1RKLB belongs to the best of the industry, outperforming 97.78% of the companies in the same industry.

A Debt/Equity ratio of 0.32 indicates that 1RKLB is not too dependend on debt financing.

With a decent Debt to Equity ratio value of 0.32, 1RKLB is doing good in the industry, outperforming 62.22% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.32
Debt/FCF	N/A
Altman-Z	11.81

ROIC/WACCN/A

WACC9.6%

2.3 Liquidity

1RKLB has a Current Ratio of 3.18. This indicates that 1RKLB is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of 1RKLB (3.18) is better than 93.33% of its industry peers.

1RKLB has a Quick Ratio of 2.83. This indicates that 1RKLB is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 2.83, 1RKLB belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.18
Quick Ratio	2.83

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

1RKLB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.70%.

1RKLB shows a strong growth in Revenue. In the last year, the Revenue has grown by 52.42%.

The Revenue has been growing by 55.23% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-2.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%70%

Revenue 1Y (TTM)52.42%

Revenue growth 3Y91.41%

Revenue growth 5Y55.23%

Sales Q2Q%47.97%

3.2 Future

The Earnings Per Share is expected to grow by 32.40% on average over the next years. This is a very strong growth

1RKLB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.95% yearly.

EPS Next Y-19.95%

EPS Next 2Y24.45%

EPS Next 3Y30.19%

EPS Next 5Y32.4%

Revenue Next Year35.91%

Revenue Next 2Y44.34%

Revenue Next 3Y40.17%

Revenue Next 5Y31.95%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 1RKLB. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1RKLB. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as 1RKLB's earnings are expected to grow with 30.19% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y24.45%

EPS Next 3Y30.19%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

1RKLB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ROCKET LAB CORP

BIT:1RKLB (11/21/2025, 7:00:00 PM)

33.78

-2.39 (-6.62%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryAerospace & Defense

Earnings (Last)11-10 2025-11-10/amc

Earnings (Next)N/A N/A

Inst Owners61.26%

Inst Owner ChangeN/A

Ins Owners0.64%

Ins Owner ChangeN/A

Market Cap16.35B

Revenue(TTM)554.53M

Net Income(TTM)-197.63M

Analysts80

Price Target56.64 (67.67%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)30.22%

Min EPS beat(2)-11.38%

Max EPS beat(2)71.81%

EPS beat(4)3

Avg EPS beat(4)18.1%

Min EPS beat(4)-11.38%

Max EPS beat(4)71.81%

EPS beat(8)7

Avg EPS beat(8)15.56%

EPS beat(12)8

Avg EPS beat(12)9.83%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)2

Avg Revenue beat(2)2.41%

Min Revenue beat(2)0.19%

Max Revenue beat(2)4.63%

Revenue beat(4)2

Avg Revenue beat(4)0.8%

Min Revenue beat(4)-0.99%

Max Revenue beat(4)4.63%

Revenue beat(8)3

Avg Revenue beat(8)-1.04%

Revenue beat(12)5

Avg Revenue beat(12)-0.56%

Revenue beat(16)8

Avg Revenue beat(16)0.96%

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)-16.76%

EPS NQ rev (3m)-17.32%

EPS NY rev (1m)0%

EPS NY rev (3m)-2.86%

Revenue NQ rev (1m)2.27%

Revenue NQ rev (3m)4.6%

Revenue NY rev (1m)0%

Revenue NY rev (3m)1.21%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	33.96
P/FCF	N/A
P/OCF	N/A
P/B	14.7
P/tB	22.66
EV/EBITDA	N/A

EPS(TTM)-0.33

EYN/A

EPS(NY)-0.14

Fwd EYN/A

FCF(TTM)-0.42

FCFYN/A

OCF(TTM)-0.19

OCFYN/A

SpS0.99

BVpS2.3

TBVpS1.49

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.9%
ROE	-15.43%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	31.7%
FCFM	N/A

ROA(3y)-16.4%

ROA(5y)-18.08%

ROE(3y)-34.28%

ROE(5y)-34.08%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.25

Health

		Industry Rank	Sector Rank
Debt/Equity	0.32
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	334.43%
Cap/Sales	23.12%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.18
Quick Ratio	2.83
Altman-Z	11.81

F-Score5

WACC9.6%

ROIC/WACCN/A

Cap/Depr(3y)174.96%

Cap/Depr(5y)206.2%

Cap/Sales(3y)19.28%

Cap/Sales(5y)34.12%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-2.7%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%70%

EPS Next Y-19.95%

EPS Next 2Y24.45%

EPS Next 3Y30.19%

EPS Next 5Y32.4%

Revenue 1Y (TTM)52.42%

Revenue growth 3Y91.41%

Revenue growth 5Y55.23%

Sales Q2Q%47.97%

Revenue Next Year35.91%

Revenue Next 2Y44.34%

Revenue Next 3Y40.17%

Revenue Next 5Y31.95%

EBIT growth 1Y-23.21%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year51.27%

EBIT Next 3Y41.55%

EBIT Next 5Y31.86%

FCF growth 1Y-71.68%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-36.74%

OCF growth 3YN/A

OCF growth 5YN/A

ROCKET LAB CORP / 1RKLB.MI FAQ

Can you provide the ChartMill fundamental rating for ROCKET LAB CORP?

ChartMill assigns a fundamental rating of 3 / 10 to 1RKLB.MI.

Can you provide the valuation status for ROCKET LAB CORP?

ChartMill assigns a valuation rating of 1 / 10 to ROCKET LAB CORP (1RKLB.MI). This can be considered as Overvalued.

Can you provide the profitability details for ROCKET LAB CORP?

ROCKET LAB CORP (1RKLB.MI) has a profitability rating of 0 / 10.

Can you provide the expected EPS growth for 1RKLB stock?

The Earnings per Share (EPS) of ROCKET LAB CORP (1RKLB.MI) is expected to decline by -19.95% in the next year.

ROCKET LAB CORP (1RKLB.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ROCKET LAB CORP / 1RKLB.MI FAQ

Can you provide the ChartMill fundamental rating for ROCKET LAB CORP?

Can you provide the valuation status for ROCKET LAB CORP?

Can you provide the profitability details for ROCKET LAB CORP?

Can you provide the expected EPS growth for 1RKLB stock?